ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2024
First-in-Human
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Recent advances in PSMA therapy - from beta to alpha.Annals of nuclear medicine · 2026Review
- Predicting tumour and organ dose in α-radiopharmaceutical therapy: aEuropean journal of nuclear medicine and molecular imaging · 2026Article
- State-of-the-art and future developments in dosimetry for SSTR- and PSMA-targeting radioligand therapies.Zeitschrift fur medizinische Physik · 2026Review
- Picolinamide-functionalized macrocyclic chelators forInorganic chemistry frontiers · 2026Article
- Evaluating the Incorporation of Picolinamide Pendants into the Macropa Scaffold for Pb(II)- and Bi(III)-Based Radiopharmaceuticals.Inorganic chemistry · 2026Article
- Review
- Emerging evidence for sequencing and combining PSMA-based therapies in prostate cancer.Nature reviews. Urology · 2026Review
- Pair production tomography enables imaging of MeV-scale gamma-emitting theranostic radionuclides.Research square · 2026Article
- Highly Efficient Extraction ofAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Refining the clinical utility of [European journal of nuclear medicine and molecular imaging · 2026Article
- Alpha Therapy Beyond TOC and TATE-Production, Quality Control, and In-Human Results for the SSTR2 Antagonist DOTA-LM3.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Assessing the feasibility of quantitative SPECT imaging for lowEJNMMI physics · 2026Article
- Lead radionuclides for theranostic applications in nuclear medicine: from atom to bedside.Theranostics · 2026Review
- Current and future perspectives on radioligand therapy in advanced prostate cancer.Therapeutic advances in medical oncology · 2026Review
- Modelling single cell dosimetry and DNA damage of targeted alpha therapy using Monte-Carlo techniques.Physical and engineering sciences in medicine · 2025Article
- Review
- Review
- Preclinical Evaluation of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Therapeutic evaluation of [European journal of nuclear medicine and molecular imaging · 2025Article
- Recommendations on the Clinical Application and Future Potential of α-Particle Therapy: A Comprehensive Review of the Results from the SECURE Project.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.